|
Mar 14
|
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label
|
|
Mar 13
|
Relative Price Strength: A Smart Strategy Amid Market Turmoil
|
|
Mar 13
|
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
|
|
Mar 12
|
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
|
|
Mar 12
|
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone
|
|
Mar 12
|
1 Growth Stock to Target This Week and 2 to Avoid
|
|
Mar 3
|
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
|
|
Mar 1
|
Q4 2024 ANI Pharmaceuticals Inc Earnings Call
|
|
Mar 1
|
ANI Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
|
|
Feb 28
|
Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today
|
|
Feb 28
|
ANI (ANIP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Feb 28
|
ANI: Q4 Earnings Snapshot
|
|
Feb 28
|
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars
|
|
Feb 28
|
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
|
|
Feb 21
|
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
|
|
Feb 19
|
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March
|
|
Feb 19
|
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
|
|
Feb 18
|
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
|
|
Feb 17
|
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?
|
|
Feb 14
|
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
|